Showing 2 posts of 2 posts found.


Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

January 17, 2020
Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …


Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes

March 26, 2019
Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …

Latest content